The U.S. Food and Drug Administration (FDA) has recently granted clearance for the clinical trials of ER-100, an experimental gene therapy developed by Life Biosciences, a company co-founded by Harvard researcher Dr. David Sinclair. This treatment is based on the Information Theory of Aging, a framework proposing that aging results not primarily from irreversible genetic damage but from the gradual loss of epigenetic information—the regulatory system that tells cells which genes to activate or silence. This theory suggests that our cells don't actually "break" as we get older; instead, they lose their "software manual" the Epigenome (the system that tells our DNA which genes to turn on or off). Over time, this "manual" gets unreadable, like a scratched CD. ER-100 uses a process called Epigenetic Reprogramming to "polish" those scratches, allowing the cell to read its original, youthful instructions and act young again. ER-100 delivers three transcription factors- Oct4, Sox2 and Klf4, collectively known as OSK- to partially reset the epigenetic state of cells without fully reverting them to stem cells.
Current longevity interventions largely focus on slowing cellular decline rather than reversing it. Common approaches include:
- NAD⁺ pathway support, through molecules such as Nicotinamide Mononucleotide and Nicotinamide Adenine Dinucleotide boosters, which act like "fuel" for cellular repair.
- Senolytics, drugs designed to selectively eliminate senescent cells (zombie cells) that accumulate with age and contribute to chronic inflammation.
While these strategies may improve cellular resilience and metabolic health, they do not restore lost tissue function once structural damage has occurred. In many neurodegenerative or ocular conditions, age-related nerve loss is considered largely irreversible. ER-100 is being tested specifically to break this limit by attempting to restore vision in patients with Glaucoma or NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a condition that causes sudden blindness by damaging the optic nerve.
By delivering OSK factors directly to retinal cells, researchers aim to determine whether partial epigenetic reprogramming can restore cellular function and potentially recover aspects of visual signaling. This trial marks a massive shift in the pharmaceutical market, moving from "pills for prevention" to high-tech Gene Therapy for actual reversal. While Sinclair’s team has the "first-mover" advantage, they are being chased by massive competitors like Altos Labs and NewLimit. If partial reprogramming proves safe and effective in retinal neurons (sensitive and complex cell type) it could open the door to applications in neurodegenerative disorders, cardiovascular disease and other age-related conditions.
Read further:
https://www.lifebiosciences.com/life-biosciences-announces-fda-clearance-of-ind-application-for-er-100-in-optic-neuropathies/
https://ipscell.com/2026/02/fda-oks-risky-pioneering-osk-rejuvenation-trial-with-sinclairs-er-100/
https://www.cell.com/cell/fulltext/S0092-8674(22)01570-7